This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Adoptive T Cell Immunotherapy for Cancer
Journal

Adoptive T Cell Immunotherapy for Cancer

Read time: 1 mins
Published:1st Jan 2015
Author: Perica K, Varela JC, Oelke M, Schneck J.
Availability: Free full text
Ref.:Rambam Maimonides Med J. 2015 Jan; 6(1): e0004.
DOI:10.5041/RMMJ.10179

Harnessing the immune system to recognize and destroy tumor cells has been the central goal of anti-cancer immunotherapy. In recent years, there has been an increased interest in optimizing this technology in order to make it a clinically feasible treatment. One of the main treatment modalities within cancer immunotherapy has been adoptive T cell therapy (ACT). Using this approach, tumor-specific cytotoxic T cells are infused into cancer patients with the goal of recognizing, targeting, and destroying tumor cells. In the current review, we revisit some of the major successes of ACT, the major hurdles that have been overcome to optimize ACT, the remaining challenges, and future approaches to make ACT widely available.

Access full article